Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Capecitabine

Trastuzumab

Irinotecan

Leucovorin

Fluorouracil

Oxaliplatin

Antineoplastic Agents, Immunological

Camrelizumab: 200mg, iv, 21d for a treatment cycle Trastuzumab: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle Chemotherapy will either be XELOX, mFOLFOX6, FOLFIRI, mXELIRI or mIRIS

Camrelizumab

8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle

Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w

XELOX regimen

Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w

mFOLFOX6 regimen

Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w

FOLFIRI regimen

Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w

mXELIRI regimen

Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w

mIRIS regimen

Zhe Zhang, PHD

This study aimed to evaluate the efficacy and safety of camrelizumab combined with trastuzumab and chemotherapy in Patients with HER2-positive advanced colorectal cancer

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer: A Prospective, Single-arm, Open-label Study

The proportion of patients with complete response or partial response according to RECIST v1.1

Time from the initiation of treatment to disease progression or any-cause death

The proportion of patients with complete response, partial response or stable disease according to RECIST v1.1

Time from the initiation of treatment to any-cause death

Time from complete response or partial response to disease progression or any-cause death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer	NCT05193292	Colorectal Neop... Intestinal Neop...	Camrelizumab Trastuzumab XELOX regimen mFOLFOX6 regime... FOLFIRI regimen mXELIRI regimen mIRIS regimen	18 Years -	Fudan University
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer	NCT05193292	Colorectal Neop... Intestinal Neop...	Camrelizumab Trastuzumab XELOX regimen mFOLFOX6 regime... FOLFIRI regimen mXELIRI regimen mIRIS regimen	18 Years -	Fudan University

Spots Global Cancer Trial Database for miris regimen